Efficacy and safety of modified rituximab-ESHAP therapy for relapsed/refractory B-cell lymphoma

Journal of Chemotherapy

Volumn 22, Issue 1, 2010, Pages 54-57

  Ueda, K ^a   Nannya, Y ^a   Asai, T ^a   Yamamoto, G ^a   Hangaishi, A ^a   Takahashi, T ^a   Imai, Y ^a   Kurokawa, Mineo ^a,b  

^a UNIVERSITY OF TOKYO   (Japan)

^b UNIVERSITY OF TOKYO HOSPITAL   (Japan)

Author keywords

Carboplatin; Cisplatin; Non Hodgkin lymphoma; Rituximab; Salvage therapy

Indexed keywords

CARBOPLATIN; CISPLATIN; CYTARABINE; ETOPOSIDE; METHYLPREDNISOLONE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; RITUXIMAB;

ADULT; AGED; ALLOGENEIC STEM CELL TRANSPLANTATION; ANEMIA; ARTICLE; B CELL LYMPHOMA; BONE MARROW SUPPRESSION; CANCER COMBINATION CHEMOTHERAPY; CANCER RELAPSE; CANCER SURVIVAL; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ERUPTION; DRUG MEGADOSE; DRUG SAFETY; FEBRILE NEUTROPENIA; FEMALE; FOLLICULAR LYMPHOMA; FOLLOW UP; HEART ARRHYTHMIA; HUMAN; HYPERGLYCEMIA; HYPERTENSION; LARGE CELL LYMPHOMA; LEUKEMIA; LEUKOPENIA; LIVER DYSFUNCTION; MALE; MULTIPLE CYCLE TREATMENT; NEPHROTOXICITY; NEUTROPENIA; OVERALL SURVIVAL; PROGRESSION FREE SURVIVAL; REFRACTORY PERIOD; SEPSIS; SIDE EFFECT; STEM CELL MOBILIZATION; THROMBOCYTOPENIA; TREATMENT RESPONSE; WEIGHT GAIN;

EID: 77950103411     PISSN: 1120009X     EISSN: 19739478     Source Type: Journal    
DOI: 10.1179/joc.2010.22.1.54     Document Type: Article

References (25)

1. Cnilfier B, Lepage E, Briere J, Herbrecht R, Tilly H, Bouabdallah R et al. CHOP chemotherapy plus rituximab cumpared with CHOP alone in elderly patients with diltuse large-B-cell lymphoma. N EngI J Med. 2002;346f4f:235-42.
2. Lin TY, Zhang HY, Huang Y, Guan ZZ, Shen T, Shi YK et al. [Comparison between R-CHOP regimen and CHOP regimen in treating naive diffuse large B-cell lymphama in China - a multi-center randomized trail]. Ai Zheng. 2005;24(12):1421-6.
3. Sehn LH, Donaldson J, Chhanabhai M, Fitzgerald C, Gill K, Klasa R at al. Introduction of combined CHOP plus rituximab therapy dramatically improved outcome of diffuse large B-cell lymphoma in British Columbia. J Clin Oncol. 2005;23(22):5027-33.
4. Seshadri T, Kuruvilla J, Crump M, Keating A. Salvage therapy for relapsed/refractory diffuse large B call lymphoma. Biol Blood Marrow Transplant. 2008:14(3):259-67.
5. Philip T, Guglielmi C, Hagenbeek A, Somers R, Van der Lelie H, Bron D at al. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma. N EngI J Med. 1995:333(23):1540-5.
6. Schouten HC, Qian W, Kvaloy S, Porcellini A, Hagberg H, Johnson HE et al. High-dose therapy improves progression-free survival and survival in relapsed follicular non-Hodgkin's lymphoma: results from the randomized European CUP trial. J Clin Oncol. 2003;21(21):39l8-27.
7. Velasquez WS, McLaughlin P, Tucker S, Hagemeister FB, Swan F, Rodriguez MA et al. ESHAP - an effective chemotherapy regimen in refractory and relapsing lymphoma: a 4-year follow up study. J Clin Oncol. 1994;12(6):1169-76.
8. Harting R, Venugopal P, Gregory SA, O'Brien T, Bogdanova E. Efficacy and safety of rituximab combined with ESHAP chemotherapy for the treatment of relapsed/refractory aggressive B-cell non-Hodgkin lymphoma. Clin Lymphoma Myeloma. 2007;7(6):406-12.
9. Martin A, Conde E, Arnan M, Canales MA, Deben G, Sancho JM et al. R-ESHAP as salvage therapy for patients with relapsed or refractory diffuse large B-cell lymphoma: the influence of prior exposure to rituximab on outcume. A GEL/TAMO study. Haematologica. 2008;93(12):1829-36.
10. Calvert AH, Newell DR, Gumbrell LA, O'Reilly S, Burnell M, Boxall FE et al. Carboplatin dosage: prospective evaluation of a simple formula based on renal function. J Clin Oncol. 1989;7(11):1748-56.
11. DeVita Ca. Cancer chemotherapy Drug Manual. 2002.
12. Cheson BD, Horning SJ, Coiffier B, Shipp MA, Fisher RI, Connors JM et al. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. J Clin Oncol. 1999;17(4):1244.
13. Rodriguez MA, Cabanillas FC, Velasquez W, Hagemeister FB, McLaughlin P, Swan F et al. Results of a salvage treatment program for relapsing lymphoma: MINE consolidated with ESHAP. J Clin Oncol. 1995:13(7):1734-41.
14. Park SH, Kim S, Ko OB, Koo JE, Lee D, Jeong YP et al. ESHAP salvage therapy for refractory and relapsed non-Hodgkin's lymphoma: a single center experience. Korean J Intern Med. 2006;21(3):159-64.
15. Daugaard G, Abildgaard U. Cisplatin nephrotoxicity. A review. Cancer Chemother Pharmacol. 1989;25(1):1-9.
16. Duffull SB, Begg EJ, Robinson BA, Deely JJ. A sequential Bayesian algorithm for dose individualisation of carboplatin. Cancer Chemother Pharmacol. 1997;39(4):317-26.
17. Go RS, Adjei AA. Review of the comparative pharmacology and clinical activity of cisplatin and carboplatin. J CIin Oncol. 1999;17(1):409-22.
18. Project TIN-HsLPF. A predictive model for aggressive nan-Hodgkin's lymphoma. The International Non-Hodgkin's Lymphoma Prognostic Factors Project. N EngI J Med. 1993;329(14):987-94.
19. Bokemeyer C, Kohrmann O, Tischler J, Weissbach L, Rath U, Haupt A et al. A randomized trial of cisplatin. etoposide and bleomycin (PEB) versus carboplatin, etoposide and bleomycin (CEB) for patients with 'goad-risk' metastatic non-seminomatous germ cell tumors. Ann Oncol. 1996;7(l0):1015-21.
20. Niitsu N, Umeda M. Salvage chemotherapy for relapsed or refractory non-Hadgkin's lymphoma with a combination of ACES (high-dose Ara C, carboplatin, etoposide and steroids) therapy. Eur J Haematol. 1996;57(4):320-4.
21. Imataki O, Tamai Y, Kawakami K. [Comparison of salvage chemotherapy regimen ACES with ESHAP for refractory or relapsed malignant lymphoma]. Gan To Kagaku Ryoho. 2007;34(10):1629-32.
22. Abali H, Urun Y, Oksuzoglu B, Budakoglu B, Yildirim N, Guler T et al. Comparison of ICE (ifosfamide-carboplatin-etoposide) versus DHAP (cytosine arabinoside-cisplatin-dexamethasone) as salvage chemotherapy in patients with relapsed or refractory lymphoma. Cancer Invest. 2008;26(4):401-6.
23. Duffull SB, Robinson BA. Clinical pharmacokinetics and daso optimisation of carboplatin. Clin Pharmacokinet. 1997:33(3):161-83.
24. McKeage MJ. Comparative adverse effect profiles of platinum drugs. Drug Saf. 1995;13(4):228-44.
25. Witzig TE, Geyer SM, Kurtin PJ, Colgan JP, Inwards DJ. Micallef IN et al. Salvage chemotherapy with rituximab DHAP far relapsed non-Hodgkin lymphoma: a phase II trial in the North Central Cancer Treatment Group. Leuk Lymphoma. 2008;49(6),1074-80.